Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/92370
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kleinrouweler, C. | - |
dc.contributor.author | Wiegerinck, M. | - |
dc.contributor.author | Ris-Stalpers, C. | - |
dc.contributor.author | Bossuyt, P. | - |
dc.contributor.author | van der Post, J. | - |
dc.contributor.author | von Dadelszen, P. | - |
dc.contributor.author | Mol, B. | - |
dc.contributor.author | Pajkrt, E. | - |
dc.date.issued | 2012 | - |
dc.identifier.citation | BJOG: an International Journal of Obstetrics and Gynaecology, 2012; 119(7):778-787 | - |
dc.identifier.issn | 1470-0328 | - |
dc.identifier.issn | 1471-0528 | - |
dc.identifier.uri | http://hdl.handle.net/2440/92370 | - |
dc.description.abstract | Background: Biomarkers have been proposed for identification of women at increased risk of developing pre-eclampsia. Objectives: To investigate the capacity of circulating placental growth factor (PlGF), vascular endothelial growth factor (VEGF), soluble fms-like tyrosine kinase-1 (sFLT1) and soluble endoglin (sENG) to predict pre-eclampsia. Search strategy: Medline and Embase through October 2010 and reference lists of reviews, without constraints. Selection criteria: We included original publications on testing of PlGF, VEGF, sFLT1 and sENG in serum or plasma of pregnant women at <30 weeks of gestation and before clinical onset of pre-eclampsia. Data collection and analysis: Two reviewers independently identified eligible studies, extracted descriptive and test accuracy data and assessed methodological quality. Summary estimates of discriminatory performance were obtained. Main results: We included 34 studies. Concentrations of PlGF (27 studies) and VEGF (three studies) were lower in women who developed pre-eclampsia: standardised mean differences (SMD) −0.56 (95% CI −0.77 to −0.35) and −1.25 (95% CI −2.73 to 0.23). Concentrations of sFLT1 (19 studies) and sENG (ten studies) were higher: SMD 0.48 (95% CI 0.21–0.75) and SMD 0.54 (95% CI 0.24–0.84). The summary diagnostic odds ratios were: PlGF 9.0 (95% CI 5.6–14.5), sFLT1 6.6 (95% CI 3.1–13.7), sENG 4.2 (95% CI 2.4–7.2), which correspond to sensitivities of 32%, 26% and 18%, respectively, for a 5% false-positive rate. Author’s conclusions: PlGF, sFLT1 and sENG showed modest but significantly different concentrations before 30 weeks of gestation in women who developed pre-eclampsia. Test accuracies of all four markers, however, are too poor for accurate prediction of pre-eclampsia in clinical practice. | - |
dc.description.statementofresponsibility | CE Kleinrouweler, MMJ Wiegerinck, C Ris-Stalpers, PMM Bossuyt, JAM van der Post, P von Dadelszen, BWJ Mol, E Pajkrt, for the EBM CONNECT Collaboration | - |
dc.language.iso | en | - |
dc.publisher | Wiley | - |
dc.rights | © 2012 The Authors | - |
dc.source.uri | http://dx.doi.org/10.1111/j.1471-0528.2012.03311.x | - |
dc.subject | Biomarkers; placental growth factor; pre-eclampsia; soluble endoglin; soluble fms-like tyrosine kinase-1; vascular endothelial growth factor | - |
dc.title | Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1111/j.1471-0528.2012.03311.x | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Mol, B. [0000-0001-8337-550X] | - |
Appears in Collections: | Aurora harvest 2 Obstetrics and Gynaecology publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.